Twitxy
Saved
@BioCentury's profile picture
View on X

BioCentury

@BioCentury

The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis: bit.ly/4b1HDDu
Redwood City, Calif. biocentury.com Joined December 2010
1.8K Following 17K Followers 40K Posts

Latest posts 5

BioCentury @BioCentury
Faster trials, novel biology, and looming U.S. investment curbs. Live from Shanghai, leaders from Kali, Aerska and Charles River join BioCentury This Week to discuss China’s growing role in global drug development and how COINS could reshape dealmaking. buff.ly/ATDAxQm
www.biocentury.com China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast • COINS and cross-border capital — U.S. restrictions are widely expected to pass, but investors and companies are already exploring licensing...
BioCentury @BioCentury
In BioCentury's Public Equity Report: Rezera proposes IPO terms despite NASDAQ volatility; Evommune funds a deal with a PIPE; Inovio draws cash after vaccine approval; Alnylam's buyback; and more buff.ly/Q0yFt5i
www.biocentury.com Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report Inflammation company Rezera proposed terms for an IPO expected to price next week, although market volatility could complicate its NASDAQ debut.In an amend...
BioCentury @BioCentury
BioCentury's analysis of emerging science from #SITC26 highlights a cluster of preclinical abstracts describing new ways to localize immune responses to tumors with cell and gene therapies buff.ly/o0LvE7h
www.biocentury.com SITC 2026: Engineering immune responses inside tumors Turning tumors into local immunotherapy factories is among the strategies highlighted in preclinical cell, gene, and mRNA therapy abstracts at SITC 2026. T...
BioCentury @BioCentury
Oxford spinout Alethio raised $90M to take its first-in-class MPIG6B antibody into the clinic for essential thrombocythemia. The goal is to lower platelet counts and shrink the malignant clone regardless of which mutation drives the disease. buff.ly/sPp3GK4
www.biocentury.com Alethio: A mutation-agnostic approach to essential thrombocythemia Alethio wants to lower platelet counts in essential thrombocythemia and shrink the malignant clone that drives their overproduction. It chose the platelet ...